Supplementary Figures 1 through 6 from Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma
Year: 2023
Type: supplementary-materials
Abstract: PDF - 476K, Figure S1. Establishment of vemurafenib-resistant A375 melanoma cell line A375RF21 from its parental A375 cell line using chronic selection over 3 months with increasing concentrations of vemurafenib; Figure S2. Anti-phospho-histone H3 and PI (propidium iodide) bivariate staining cell cycle analysis on vemurafenib-resistant cells; Figure S3. In vitro dose-response curves (n = 5) of each combination in A375 and A375RF21 cells; Figure S4. Major vemurafenib resistance mechanisms in A375RF21 cells are the over-expression of PDGFβ and the activations of the PI3K-AKT pathway; Figure S5. Effect of single agent and combination treatment on purified-protein based tubulin polymerization assay (n = 3); Figure S6. In vitro growth curve for A375 and vemurafenib-resistant subline A375RF21 cells.
Authors: Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li
Institution: University of Tennessee Health Science Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362494710